GET DAILY SIGNALSZimmer Biomet Holdings, Inc. (ZBH) Shows Steady Progress in Q3 Despite Knee Headwinds
Key Takeaways
- Zimmer Biomet reported third-quarter 2026 net sales of $2.063 billion, up 3.1% on a reported basis and 3.7% in constant currency.
- Adjusted diluted earnings per share (EPS) came in at $1.90, roughly in line with the prior-year quarter and modestly above analyst consensus estimates.
- GAAP (Generally Accepted Accounting Principles) diluted EPS was $1.00, down from $1.16 a year earlier, reflecting higher selling and transformation-related costs.
- Hips, the S.E.T. franchise, and Technology & Data segments grew strongly, while the company's largest category, Knees, continued to decline.
- Management raised its full-year 2026 outlook for both organic constant-currency revenue growth and adjusted EPS.
- For more on this company, explore its Major News, Today's Price Move, Price Targets, and Forecast.
- Discover additional market opportunities with Trending AI Robots.
Earnings Context and Why It Matters
Zimmer Biomet's third-quarter report offers investors a progress check on the company's multi-year effort to diversify beyond its core joint-replacement franchise into faster-growing areas such as robotics, data solutions, and extremities. Coming after several quarters of softness in the knee business, the results matter because they reveal whether that headwind is being offset by momentum elsewhere in the portfolio. The quarter also carried significance as management continued a U.S. sales-force transition designed to sharpen commercial execution, a restructuring that has created near-term disruption. With the company approaching its 100-year anniversary and relying on its Paragon 28 acquisition to accelerate foot-and-ankle growth, this earnings release was a key test of whether its diversification strategy can sustain consolidated growth. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Zimmer Biomet posted third-quarter 2026 net sales of $2.063 billion, a 3.1% increase on a reported basis and 3.7% on a constant-currency basis, exceeding the consensus revenue estimate of roughly $2.04 billion. GAAP diluted EPS was $1.00, down from $1.16 in the prior-year quarter, while adjusted diluted EPS was $1.90, flat year over year and slightly above analyst estimates.
Results were uneven across the portfolio. Hips sales rose 6.0% on a reported basis (7.0% in constant currency), and the S.E.T. category (Sports Medicine, Biologics, Foot and Ankle, Upper Extremities, Trauma, Craniomaxillofacial and Thoracic) grew 6.8% reported and 7.1% in constant currency. Technology & Data, Bone Cement and Surgical climbed 11.9% reported and 13.0% in constant currency. In contrast, Knees — the company's largest product category — declined 3.1% on a reported basis and 2.6% in constant currency, weighed down by the U.S. sales-force transition and competitive and China-related pressures.
The company generated $560.0 million in operating cash flow and $372.4 million in free cash flow, both up roughly 34% year over year. Management also raised full-year 2026 guidance, lifting organic constant-currency sales growth to a range of 3.0% to 3.5% and adjusted EPS to a range of $8.50 to $8.60.
Market Reaction and Investor Sentiment
Heading into the report, sentiment was cautious, reflecting persistent concerns about knee weakness and the disruptive U.S. sales-force transition. The top-line beat and the upward revision to full-year guidance provided a positive offset, while the decline in GAAP earnings and the year-over-year dip in adjusted operating margin underscored the cost of the commercial restructuring. Early trading showed a modestly negative move in the shares, suggesting investors were weighing the encouraging diversification momentum against ongoing knee headwinds and elevated spending. Overall, the results reinforced the view that Zimmer Biomet's growth is becoming broader-based even as its largest franchise continues to lag. From what I see, this balance is worth monitoring closely in the quarters ahead.
Forward Outlook and Key Factors to Monitor
Management's raised guidance signals growing confidence in the diversification strategy, but several items will shape the narrative in coming quarters. First, investors should watch the U.S. sales-force transition, which is now roughly three-quarters complete. Management indicated the disruption is running ahead of schedule and less severe than initially expected, yet knees remain under pressure and are not expected to stabilize until the transition matures.
Second, the robotics and enabling-technology pipeline is a key catalyst. Zimmer Biomet expects to file a 510(k) application for its Monogram robotic system soon — significantly ahead of schedule — and now anticipates launching a fully autonomous version in the first half of 2027. Progress on hiring robotics sales specialists and the continued rollout of the Z1 hip stem and OrthoGrid platforms will be closely monitored.
Finally, margin and cost trends remain important. The company cited a roughly 46% operating-expense-to-sales ratio and is consolidating manufacturing facilities in Warsaw, Indiana, while shifting international production toward lower-cost locations. How quickly these efficiency initiatives translate into operating-margin improvement will be central to the stock's next leg. China-related headwinds are also expected to anniversary in early 2027, potentially easing pressure on international knees.
Using Tickeron’s AI Tools for Deeper Analysis
In my view, tools like Tickeron’s AI Screener can help investors quickly compare Zimmer Biomet (ZBH) with peers in the medical device space and track momentum shifts across segments. I find it useful for spotting patterns in fundamentals and technical signals that might otherwise take hours to review manually. This kind of analysis supports a more informed perspective on how the company’s diversification efforts are playing out relative to the broader sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ZBH in upward trend: price rose above 50-day moving average on November 02, 2026
ZBH moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend. In 35 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on ZBH as a result. In 58 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for ZBH just turned positive on October 12, 2026. Looking at past instances where ZBH's MACD turned positive, the stock continued to rise in 29 of 44 cases over the following month. The odds of a continued upward trend are 66%.
The 10-day moving average for ZBH crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.
Following a +1.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZBH advanced for three days, in 196 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 126 of 221 cases where ZBH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Bearish Trend Analysis
The 10-day RSI Indicator for ZBH moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 21 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 64%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 57 cases where ZBH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZBH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
ZBH broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ZBH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.467) is normal, around the industry mean (4.170). P/E Ratio (23.558) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (0.576) is also within normal values, averaging (11.253). Dividend Yield (0.010) settles around the average of (0.010) among similar stocks. P/S Ratio (2.233) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZBH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a mobile application software
Industry MedicalNursingServices
Advertisement